+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

DPP-IV Inhibitors - Global Strategic Business Report

  • PDF Icon

    Report

  • 262 Pages
  • May 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1946785
Description Jump to:
The global market for DPP-IV Inhibitors is estimated at US$11.7 Billion in 2023 and is projected to reach US$13.2 Billion by 2030, growing at a CAGR of 1.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

  • Regional Analysis: Gain insights into the U.S. market, estimated at $3.4 Billion in 2023, and China, forecasted to grow at an impressive 1.7% CAGR to reach $2.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global DPP-IV Inhibitors Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global DPP-IV Inhibitors Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global DPP-IV Inhibitors Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AstraZeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 16 Featured):

  • AstraZeneca Plc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Outlook for DPP-IV Therapies Remains Moderate Due to CVD Risks
  • Major DPP-4 Inhibitors on the Market: List of Brand, Preparation, Manufacturer, Daily Treatment Cost, FDA Approval Date and Patent Expiration Date
  • Recent Market Activity
  • TECOS Results Prove No Link of Januvia with CVD Events; However, FDA Adds Heart Failure Warning to Label
  • Management of T2DM with DPP-4 Combination Therapy
  • FDA Approves Merck’s First SGLT-2 and DPP4 Combination Drug On Basis of Benefits over DPP-4 Inhibitor Monotherapy
  • DPP-IV Inhibitors - Global Key Competitors Percentage Market Share in 2024 (E)
  • Global Economic Update
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
  • AstraZeneca Plc. (UK)
  • Boehringer Ingelheim GmbH (Germany)
  • Eli Lilly and Company (USA)
  • Merck & Co, Inc. (USA)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Novartis AG (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 2: World 7-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • Table 3: World DPP-IV Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 4: USA Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
CANADA
  • Table 5: Canada Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
JAPAN
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 6: Japan Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
CHINA
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 7: China Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
EUROPE
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 8: Europe Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: Europe 7-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
FRANCE
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 10: France Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
GERMANY
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 11: Germany Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
ITALY
  • Table 12: Italy Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
UNITED KINGDOM
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 13: UK Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
REST OF EUROPE
  • Table 14: Rest of Europe Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
ASIA-PACIFIC
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 15: Asia-Pacific Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
REST OF WORLD
  • Table 16: Rest of World Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca Plc.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages262
PublishedMay 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 11.7 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.2 Billion
Compound Annual Growth Rate1.7%
Regions CoveredGlobal

Related Topics

Related Reports

DPP IV Inhibitor (DPP-4 Inhibitor) Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type - Product Image

DPP IV Inhibitor (DPP-4 Inhibitor) Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 104 Pages
  • Global
From
Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034 - Product Image

Dipeptidyl Peptidase IV (DPP-4) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

  • Report
  • 120 Pages
  • Global
From
Diabetes Drugs Market, Size, Global Forecast 2023-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis - Product Image

Diabetes Drugs Market, Size, Global Forecast 2023-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis

  • Report
  • 220 Pages
  • Global
From
Brazil Diabetes Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029 - Product Image

Brazil Diabetes Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

  • Report
  • 70 Pages
  • Brazil
From

About the Market

DPP IV inhibitors are a class of drugs used to treat type 2 diabetes. They work by blocking the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down the hormone incretin. This helps to increase the amount of incretin in the body, which in turn helps to reduce blood sugar levels. DPP IV inhibitors are usually taken in combination with other diabetes drugs, such as metformin, sulfonylureas, or thiazolidinediones. They are generally well tolerated and have few side effects. The DPP IV inhibitor market is a growing segment of the diabetes drug market. It is expected to continue to grow as more people are diagnosed with type 2 diabetes and the need for effective treatments increases. The market is highly competitive, with many companies offering different types of DPP IV inhibitors. Some of the major players in the market include Novo Nordisk, Merck, Sanofi, Eli Lilly, and Boehringer Ingelheim. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.